Prazosin kinetics in hypertension. 1981

A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr

Prazosin kinetics were studied after single doses (intravenous and oral, 0.5 mg) and after increasing multiple doses (0.5 to 5 mg three times daily) in eight patients with hypertension. After intravenous administration the kinetics could be described by a linear two-compartment open model. Terminal half-life (t1/2 beta) was about 3 hr and apparent volume of distribution (Vd beta) about 0.6 l/kg. After oral doses bioavailability ranged between 55% and 82%. Since total plasma clearance was low (0.14 l/kg x hr) incomplete bioavailability was the result of incomplete absorption rather than of first-pass liver metabolism. The estimated extraction ratio was about 14%. Renal clearance was negligible; only 1% to 2% of the dose was recovered unchanged in urine. Binding to plasma proteins to both albumin and alpha 1-acid glycoprotein was substantial (97%), with albumin being most important. Increasing multiple doses showed that prazosin followed first-order kinetics with a linear correlation between dose and steady-state plasma concentration (P less than 0.001). There were substantial variations in plasma concentrations between patients and there were also day-to-day variations in concentration within the same patient.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D005260 Female Females

Related Publications

A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
July 1980, Clinical pharmacology and therapeutics,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
October 1990, American journal of hypertension,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
November 1976, British medical journal,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
September 1981, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
January 1979, Indian heart journal,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
October 1974, British medical journal,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
November 1977, American family physician,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
September 1981, The Practitioner,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
January 1977, The Medical letter on drugs and therapeutics,
A Grahnén, and P Seideman, and B Lindström, and K Haglund, and C von Bahr
June 1980, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!